SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : CTEC: Cholestech any other investors? -- Ignore unavailable to you. Want to Upgrade?


To: Boplicity who wrote (363)12/16/1997 4:44:00 PM
From: John Kratus  Read Replies (2) | Respond to of 710
 
Greg, CNTO is in a completely different business. Here is the Yahoo summary:

"CNTO is a biotechnology company formed to develop and commercialize therapeutic and diagnostic products and services with a primary technological focus on monoclonal antibodies and DNA-based products."

The company's failure to meet anaylsts' expections can be blamed on this:

<<Centocor falls on impatience over Avakine

NEW YORK, Dec 12 (Reuters) - Shares of Centocor Inc (Nasdaq:CNTO - news) fell sharply Friday on investor impatience about how soon the company would seek a European marketing partner for its anti inflammatory drug Avakine and when the drug will be launched in the United States, analysts said.

Shares ended 5-1/4 lower to 34-3/4.

Morgan Stanley biotech analyst Douglas Lind said investors reacted to comments made, and comments not made, by Centocor chief executive David Holveck at a dinner honoring him in Manhattan Thursday.

Lind said investors were disappointed Holveck failed to announce a European marketing partner for Avakine (infliximab), which completed Phase III trials earlier this year for treatment of Crohn's Disease.

''Somehow they were expecting an announcement and it didn't happen,'' Lind said, adding he believed the announcement would indeed be made soon.>>

CTEC is safe and strong. Getting safer and stronger today, too. I hope nobody here dumped shares at 9 5/8.

John